Dendrimers Integration in Cancer Imaging and Theranostics: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Subjects: Oncology
Contributor:
Adriana Cruz
,
José Barbosa
,
Patrícia Antunes
,
Vasco D. B. Bonifácio
,
Sandra N. Pinto

Cancer is a result of abnormal cell proliferation. This pathology is a serious health problem since it is a leading cause of death worldwide. Anti-cancer therapies rely on surgery, radiation, and chemotherapy. However, these treatments still present major associated problems, namely the absence of specificity. Nanoparticles, particularly dendrimers, have been paving their way to the front line of cancer treatment, mostly for drug and gene delivery, diagnosis, and disease monitoring. This is mainly derived from their high versatility, which results from their ability to undergo distinct surface functionalization, leading to improved performance. 

  • cancer
  • nanocarriers
  • anticancer dendrimers
  • intracellular targeting
  • theranostics

1. Introduction

All types of human cells may suffer an abnormal proliferation that can lead to cancer cells. Cancer classification/identification is performed according to the tissue and cell type from which the cancer cells arise. Therefore, there are multiple distinct types of cancer, which can vary significantly in their behavior and response to treatments [1]. This disease is a major public health problem and a leading cause of death worldwide in countries of all income levels.
According to the World Health Organization (WHO), the social and economic impact caused by cancer is increasing. In a 2014 report, an annual cost of EUR 1.04 trillion was estimated for global cancer expenses. The report also declared that it is important to continue investing in care and control, which will prevent a considerable number of deaths for years to come. [2]. Extended lifespan associated with environmental factors (e.g., exposure to pollution, carcinogenic agents, radiation, viruses and bacteria) and the low efficacy of available treatments, closely associated with an increased drug resistance, also contributes to cancer development [3].
Currently, the standard cancer treatments used in clinical settings are radiotherapy, surgery, and conventional chemotherapy [4]. However, these therapies present several drawbacks, such as high toxicity, due to insufficient selectivity and unspecific targeting of cancer cells, which leads to increased resistance to anticancer drugs.
It is therefore relevant to find new anticancer agents able to control tumor growth with minimal side effects. In recent years, the use of nanotechnology in cancer treatment has offered some exciting possibilities, including improvement of detection and elimination of cancer cells before tumor development. This includes the use of dendrimer-based nanotherapeutics as a novel strategy for diagnosis and therapy (theranostics) [5][6][7]. Dendrimers are synthetic 3D polymers with well-defined layered architecture [8]. Owing to their high functionality and loading capacity, as well as their precisely controlled chemical composition and molecular weight, dendrimer-based anticancer therapies offer great advantages over conventional formulations. These include the use of dendrimers as advanced contrast agents (diagnosis) [6], nanocarriers (treatment) [5][9], and theranostic agents (diagnosis, treatment and disease monitoring) [7]. In the quest for new anticancer drugs using dendrimer-based therapies, Shao et al. demonstrated that dendrimers may display innate anticancer activity and anti-metastatic properties without the loading of any therapeutic agent [10].

2. Dendrimer Nanoparticles

Multifunctional nanoparticles display great potential for drug and gene delivery, especially for cancer therapy [11][12]. Dendrimers are a class of hyperbranched synthetic polymers with a very low polydispersity, also known as “cascade polymers” [13]. Biologically, dendrimers are highly biocompatible, with a predictable biodistribution and cell-membrane-interacting features mostly determined by their size and surface charge [14]. They were first synthesized in the late 1970s by Tomalia et al., with the desire to mimic a common pattern in nature with vast potential applications [15]. Due to their hyperbranched structure, dendrimers are extremely versatile macromolecules. Their structure can be defined by three main elements: the inner core, repetitive branching units (dendrons), and terminal groups that provide surface tuning (Figure 1) [16].
Figure 1. Schematic representation of a dendrimer nanoparticle, showing the core, repetitive branching units (dendrons) that constitute the growing layers (generations, G) and terminal groups (functional surface).
Dendrimers are classically obtained by two main approaches: a divergent or a convergent synthesis. In the first methodology, the dendrimer structure is constructed starting from a core molecule. The core reacts with monomers containing one reactive group and two dormant groups originating the first generation (G1) dendrimer. Then, the periphery of the G1 dendrimer may be activated for reaction with more monomers forming the second-generation dendrimer (G2), and so on. The divergent approach typically originates lower dendrimer generations of open structures and asymmetric shape [16]. In the convergent approach, the individual branches (dendrons) are first synthetized and then attached to a functional core molecule [17]. This methodology minimizes the occurrence of structural problems and facilitates the purification of the product [16]. Later, with the development of “click chemistry” [18], the preparation of dendronized systems became more efficient, requiring minimal purification [19]. She et al. [20], for instance, synthetized G2-poly-L-lysine dendrons that were connected at the core to a heparin sulphate moiety via “click chemistry”, and doxorubicin (DOX) was conjugated to the terminal ends using acyl hydrazine. As a consequence of the dendrimer architecture, the number of peripheral groups increases exponentially with generations, which results in nanosized particles suitable for drug loading and release [21]. However, when a critical branched state is reached, dendrimers cannot grow further because of the steric restriction imposed by the increasing branch density. This phenomenon is known as the “starburst effect” and is usually observed in high generations [16].
Since the discovery of these polymers [15], a variety of dendrimers have been developed, polyamidoamine (PAMAM) being the most studied [22]. PAMAM dendrimers are synthetized by the divergent method, mostly using an ethylenediamine core, and are hydrophilic, biocompatible, and non-immunogenic. Polypropylene imine (PPI) dendrimers, along with PAMAM, have been also widely investigated. PPIs are based on a 1,4-diaminobutane core or similar molecules and grow via double Michael addition reactions [13]. Poly-L-lysine (PLL) dendrimers are amino-acid-based polymers [23] that differ from PAMAM and PPI dendrimers in shape, since they are mostly asymmetrical. They have lysines as branching units and amines as terminal groups [22]. Phosphorous-based dendrimers are another interesting and well-studied class of dendrimers [24]. The potential of phosphorous dendrimers has been largely demonstrated, especially as cancer therapeutics. Similarly, carbosilane dendrimers have been explored as antimetastatic agents when complexed with ruthenium derivatives [25].
The different classes of dendrimers and their chemical structures are summarized in Table 1.
Table 1. Summary of different classes of dendrimers depicted in above section.

Classes of Dendrimers

Chemical Structure

PAMAM

Ethylenediamine-based core and terminal groups with primary amines

PPL

Amino acid lysine-base core and branching units

PPI

1,4-Diaminobutane-based core and terminal groups with primary amines

Phosphorous dendrimers

P-Cl-based core, azabisphosphonates are possible terminal groups

Carbosilane dendrimers

Si-based dendrimer

3. Dendrimers General Role in Cancer

Dendrimers can be used in a vast number of theranostic applications [26][27][28][29]. It is, therefore, important to be aware of the properties they have to display in order to be employed as biomedical devices. Biocompatibility is crucial to preventing undesirable responses from the host, a property that can only be defined depending on specific applications [29]. In order to prevent bioaccumulation and consequent toxicity, biodegradability is a must. Another important aspect for the development of biomedical devices is their pharmacokinetics, namely their fate in the body after administration [29]. Additionally, the water solubility of dendrimer–drug conjugates enhance the bioavailability of poorly soluble drugs [30]. Lastly, polyvalence, i.e., the ability to support versatile surface functionalization and multiple interactions with biological receptors, is a key property for highly versatile platforms [27].
Dendrimers, as shown in several studies, have a high potential to be used as nanocarriers for both diagnostic and therapeutic approaches [31][32]. Dendrimer–drug interactions might occur in many ways and are dependent on multiple factors such as size, charge, or the chemical nature of the dendrimer/drug. The chemistry behind nanocarriers is the same used in diagnostic or therapeutic schemes, with the agent selected for conjugation being the key player. In general, dendrimers could be used as nanocarriers via two major approaches: loading or conjugation at the surface of the drug and/or target molecule. Encapsulation solves solubility problems indicated by many chemotherapeutics and drugs in general. When a drug is entrapped into the dendrimer’s cavity, the polymer works as a dendritic box [33][34]; in this case, the dendrimers can cargo the drug of interest by forming structures that are stabilized via non-covalent interactions. In a different context, dendrimers could also be used as gene vectors, especially cationic dendrimers. When the strategy is dendrimer–drug conjugation, systemic effects can be reduced, increasing the efficacy of cellular targeting. This strategy also improves the half-life of the drug. The conjugate linker is also key to understanding release mechanisms. In many cases, ester and amide conjugate linkers are used that allow enzymatic or hydrolytic cleavage [34][35], easier for esters than amides [36]. Dendrimer–drug conjugation may influence the efficacy of drug itself. Importantly, these nano-polymers can cross cellular barriers by transcellular or paracellular pathways.
To use dendrimers as an alternative diagnostic tool or improve the properties of a contrast agent, it is important to guarantee some criteria. Dendrimers offer many advantages to improve the free delivery of contrast agents or drugs, including high solubility and low polydispersity, which are properties of all dendrimer classes (Table 2).
Table 2. Suitable properties of dendrimers to be used as delivery systems in different strategies.

Properties

Observations

References

Low polydispersity index

Common to all classes of dendrimers

[37][38]

EPR effect

Size/generation/Mw dependent

[39]

Permeability towards BBB

Already observed for PAMAM dendrimers

[40][41][42][43]

Highly solubility

Common to the majority of dendrimer classes

[44][45]

Multifunctional platform

Common to all classes of dendrimers

[46]

Highly loading capacity

Size/generation/Mw dependent

[47]

Stability

Common to all classes of dendrimers

[39]

Low toxicity and immunogenicity

Size/generation/Mw/charge dependent

[48][49][50]

EPR: enhanced permeability and retention, BBB: blood–brain barrier.

4. Dendrimers Cellular Uptake and Mechanism of Action at Cell Organelle Level

Dendrimers and other nanosized particles naturally accumulate in tumor sites by a possible enhanced permeability and retention (EPR) effect. This happens because the tumor microenvironment is rich in blood vessels due to increased angiogenesis. Using the blood vessels surrounding tumors, the nanoparticles can be driven into the tumors, crossing cellular barriers by transcellular or paracellular pathways [34][51]. The main question at this point is: how does the intracellular transportation of these macromolecules occur? In the case of dendrimers, their entry into target cells via direct penetration or endocytosis pathways has been described [52] (Figure 2). Importantly, the biodistribution and retention of the nanoparticles are the foremost determinants, since their diffusion and adhesion properties significantly depend on size and uptake efficiencies [53]. NPs possess biomimetic features due to their size, which is in the same range of biomolecules such as antibodies, nucleic acids, proteins, and membrane receptors. Cellular uptake, toxicity, targeting, and intracellular trafficking of NPs can be optimized by tuning physicochemical properties of NP such as size, shape, and surface properties [54]. These properties determine their uptake into mammalian cells, normally achieved by endocytosis, a form of active transport that can be classified into two major categories: phagocytosis and pinocytosis [54].
Figure 2. Schematic representation of dendrimer intracellular transportation. In general, dendrimers enter the target cells via direct penetration or endocytosis pathways. At cell level, dendrimers that follow the endocytic pathway are released from endosomes and migrate to lysosomes. Then these macromolecules can be released from lysosomes through a ‘’proton-sponge’’ effect as shown for poly(propylene imine) dendrimers. Adapted from [51].
Briefly, phagocytosis occurs in specialized cells, designated phagocytes, and consists of the internalization of large particles such as debris, bacteria or other large-size solutes. In this process, the target particle is coated with specific molecules (opsonins) that trigger its internalization and is then ingested by the cell and compartmentalized to a phagosome (plasma-membrane-derived vesicle). In the intracellular space, the phagosome fuses with the lysosome and the particle is digested at acidic pH. On the other hand, pinocytosis is a continuous process that consists in the formation of a plasma membrane invagination to capture small droplets of extracellular fluid and the molecules dissolved in it, which can be, for instance, biomolecules and nutrients. Pinocytosis can be subcategorized into clathrin-mediated endocytosis, caveolae-mediated endocytosis, and macropinocytosis, depending on the aim and specificity of the process.
Kitchens et al. studied the cellular uptake of dendrimers. Their work demonstrated that cationic and anionic PAMAM dendrimers enter the cells by a endocytosis mechanism [55]. Using lysosomal marker protein 1 (LAMP1), the authors observed that PAMAMG2-NH2 and PAMAMG1.5-CO2H dendrimers co-localized at the lysosome level at different time points depending on dendrimer surface charge. The authors also observed a decrease in PAMAMG4-NH2 uptake when the endocytic pathway was blocked using different inhibitors (brefeldin A, colchicine, filipin) [56]. In HeLa cells (cervical cancer cells), PAMAM dendrimers were shown to be internalized by two major mechanisms: clathrin-dependent endocytosis and macropinocytosis [57].
In addition to endocytosis, the uptake of polycationic polymers by cancer cells can follow a direct penetration pathway (with or without pore formation). Seungpyo Hong et al. reported the interaction of cationic dendrimers with supported lipid bilayers. The main conclusion was that these NPs can enter a cell membrane model by inducing pore formation. Applying atomic force microscopy (AFM), the authors observed that cationic PAMAM dendrimers can form holes/pores in the lipidic membrane and can also remove lipidic molecules from existing membrane defects. The authors also evaluated cell membrane recovery after dendrimer removal and found that hole/pore formation can be reversible [58]. The pore-forming ability of cationic molecules such as dendrimers and peptides can be used to develop formulations for anticancer therapy, as this mechanism of action can potentially lead to cell death [59][60].
Importantly, positively charged surface groups produce a localized charge density that is known to influence the interaction (and consequent toxicity) of dendrimers with cell membranes that possess a relevant content of negatively charged groups (as observed for the plasma membrane of cancer cells) [49]. Cellular permeability is also affected by the dendrimer generation (i.e., size). For instance, PAMAMG2 shows higher permeability rates than PAMAMG4 [61].
Dendrimers can then be designed to target a specific organelle or tissue (with a distinct mechanism of action) and induce, for instance, less side effects to normal/healthy cells. Chemical modifications in the dendrimer core or surface can improve dendrimer–cell interactions, as illustrated bellow (Figure 3). Aleksandra Szwed et al. studied the interaction mechanisms of hybrid carbosilane–viologen–phosphorus dendrimers (SMT1 and SMT2) with two different murine cell lines. These dendrimers present two distinct cationic groups (internal and outer) that are specific for mitochondria, inducing perturbations in mitochondrial membrane potential and the formation of reactive oxigen species (ROS) [62].
 
Figure 3. Schematic representation of potential intracellular cellular organelles (including plasma membrane, lipid droplets, cell nucleus, and mitochondria) targeted by dendrimers used in anticancer strategies. Cationic surface of cationic modified dendrimers is known to strongly interact with negatively charged lipids present in cancer cell membranes. Cationic dendrimers are also shown to specifically target mitochondria.
In another study, the impact and target of PAMAM dendrimer generation (G4, G5, G6) on mitochondria and other cellular organelles such as lysosomes was evaluated in HaCaT (human epidermal keratinocyte cells) and SW480 (primary adenocarcinoma) cell lines [63]. In general, SW4810 cells were more sensitive to these cationic dendrimers than HaCaT cells. After treatment, the production of ROS was higher in SW480 and reached a maximum after 4 h of exposure. These results suggest the specificity of PAMAM dendrimers towards cancer cell mitochondria in comparison to normal cells [64]. The increase in ROS and the expression of apoptotic markers such as BAX and PARP are well reported for the activity of dendrimers used in anticancer strategies [65].
The therapeutic potential of TRPDs in several in vitro models (HepG2, MCF-7 or SKOV3 cells) was evaluated as described above [66]. The results show a good cytotoxic profile against chemoresistance cell lines (MCF-7/ADR and SKOV3/ADR cells), and it was found that the mechanism of action is related to significant supramolecular interactions with DNA through the tryptophan residues [66].
One of the main patterns of cancer cells is the dysregulation of lipid metabolism, leading to a high content of lipid droplets (LDs). LDs are subcellular organelles with nano to micron diameter sizes with the ability to store high amounts of cholesterol or fatty acids, thus allowing cancer cells to avoid cytotoxic processes. The high fatty acid content can also provide an extra source of energy to cancer cells. Importantly, LDs are also associated with proliferation, invasion, metastasis, and chemoresistance processes. Thus, LDs can be viewed as future cancer hallmarks. Intracellular targeting of lipid droplets is also now becoming an imaging tool to monitor cancer cells and the targets of innovative therapeutic approaches [67]. Using “click” chemistry, multivalent niacin–polymeric (including dendrimer) conjugates were shown to target LDs [68]. The production of nitric oxide (NO) following treatment was significantly increased and a reduction in a LD relevant enzyme (diacylglycerol acyltransferase, DGAT2) involved in triglyceride biosynthesis was observed [67]. This strategy can be applied in the future for the treatment of cancer and other diseases that involve the accumulation of triglycerides/LDs.

This entry is adapted from the peer-reviewed paper 10.3390/ijms24065430

References

  1. Hassanpour, S.H.; Dehghani, M. Review of cancer from perspective of molecular. J. Cancer Res. Pract. 2017, 4, 127–129.
  2. McGuire, S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv. Nutr. 2016, 7, 418–419.
  3. Parsa, N. Environmental factors inducing human cancers. Iran J. Public Health 2012, 41, 1–9.
  4. Pérez-Herrero, E.; Fernández-Medarde, A. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Eur. J. Pharm. Biopharm 2015, 93, 52–79.
  5. Quintana, A.; Raczka, E.; Piehler, L.; Lee, I.; Myc, A.; Majoros, I.; Patri, A.K.; Thomas, T.; Mulé, J.; Baker, J.R., Jr. Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm. Res. 2002, 19, 1310–1316.
  6. Wiener, E.C.; Brechbiel, M.W.; Brothers, H.; Magin, R.L.; Gansow, O.A.; Tomalia, D.A.; Lauterbur, P.C. Dendrimer-based metal chelates: A new class of magnetic resonance imaging contrast agents. Magn. Reson. Med. 1994, 31, 1–8.
  7. Alibolandi, M.; Hoseini, F.; Mohammadi, M.; Ramezani, P.; Einafshar, E.; Taghdisi, S.M.; Ramezani, M.; Abnous, K. Curcumin-entrapped MUC-1 aptamer targeted dendrimer-gold hybrid nanostructure as a theranostic system for colon adenocarcinoma. Int. J. Pharm. 2018, 549, 67–75.
  8. Restani, R.B.; Morgado, P.I.; Ribeiro, M.P.; Correia, I.J.; Aguiar-Ricardo, A.; Bonifácio, V.D. Biocompatible polyurea dendrimers with pH-dependent fluorescence. Angew. Chem. Int. Ed. Engl. 2012, 51, 5162–5165.
  9. Wu, Y.; Sefah, K.; Liu, H.; Wang, R.; Tan, W. DNA aptamer-micelle as an efficient detection/delivery vehicle toward cancer cells. Proc. Natl. Acad. Sci. USA 2010, 107, 5–10.
  10. Shao, S.; Zhou, Q.; Si, J.; Tang, J.; Liu, X.; Wang, M.; Gao, J.; Wang, K.; Xu, R.; Shen, Y. A non-cytotoxic dendrimer with innate and potent anticancer and anti-metastatic activities. Nat. Biomed. Eng. 2017, 1, 745–757.
  11. Sanvicens, N.; Marco, M.P. Multifunctional nanoparticles--properties and prospects for their use in human medicine. Trends Biotechnol. 2008, 26, 425–433.
  12. Rodríguez-Acosta, G.L.; Hernández-Montalbán, C.; Vega-Razo, M.F.S.; Castillo-Rodríguez, I.O.; Martínez-García, M. Polymer-dendrimer Hybrids as Carriers of Anticancer Agents. Curr. Drug Targets 2022, 23, 373–392.
  13. Buhleier, E.; Wehner, W.; VÖGtle, F. “Cascade”- and “Nonskid-Chain-like” Syntheses of Molecular Cavity Topologies. Synthesis 1978, 1978, 155–158.
  14. Heegaard, P.M.; Boas, U.; Sorensen, N.S. Dendrimers for vaccine and immunostimulatory uses. A review. Bioconjug Chem. 2010, 21, 405–418.
  15. Tomalia, D.A.; Baker, H.; Dewald, J.; Hall, M.; Kallos, G.; Martin, S.; Roeck, J.; Ryder, J.; Smith, P. A New Class of Polymers: Starburst-Dendritic Macromolecules. Polym. J. 1985, 17, 117–132.
  16. Wu, L.P.; Ficker, M.; Christensen, J.B.; Trohopoulos, P.N.; Moghimi, S.M. Dendrimers in Medicine: Therapeutic Concepts and Pharmaceutical Challenges. Bioconjug Chem. 2015, 26, 1198–1211.
  17. Hawker, C.J.; Frechet, J.M.J. Preparation of polymers with controlled molecular architecture. A new convergent approach to dendritic macromolecules. J. Am. Chem. Soc. 1990, 112, 7638–7647.
  18. Kolb, H.C.; Finn, M.G.; Sharpless, K.B. Click Chemistry: Diverse Chemical Function from a Few Good Reactions. Angew. Chem. Int. Ed. Engl. 2001, 40, 2004–2021.
  19. Dockery, L.; Daniel, M.C. Dendronized Systems for the Delivery of Chemotherapeutics. Adv. Cancer Res. 2018, 139, 85–120.
  20. She, W.; Li, N.; Luo, K.; Guo, C.; Wang, G.; Geng, Y.; Gu, Z. Dendronized heparin-doxorubicin conjugate based nanoparticle as pH-responsive drug delivery system for cancer therapy. Biomaterials 2013, 34, 2252–2264.
  21. Lo, S.T.; Kumar, A.; Hsieh, J.T.; Sun, X. Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry. Mol. Pharm. 2013, 10, 793–812.
  22. Palmerston Mendes, L.; Pan, J.; Torchilin, V.P. Dendrimers as Nanocarriers for Nucleic Acid and Drug Delivery in Cancer Therapy. Molecules 2017, 22, 1401.
  23. Rahimi, A.; Amjad-Iranagh, S.; Modarress, H. Molecular dynamics simulation of coarse-grained poly(L-lysine) dendrimers. J. Mol. Model. 2016, 22, 59.
  24. Caminade, A.M. Phosphorus Dendrimers as Nanotools against Cancers. Molecules 2020, 25, 3333.
  25. Maroto-Díaz, M.; Elie, B.T.; Gómez-Sal, P.; Pérez-Serrano, J.; Gómez, R.; Contel, M.; Javier de la Mata, F. Synthesis and anticancer activity of carbosilane metallodendrimers based on arene ruthenium(ii) complexes. Dalton Trans. 2016, 45, 7049–7066.
  26. Lee, C.C.; MacKay, J.A.; Fréchet, J.M.J.; Szoka, F.C. Designing dendrimers for biological applications. Nat. Biotechnol. 2005, 23, 1517–1526.
  27. Abbasi, E.; Aval, S.F.; Akbarzadeh, A.; Milani, M.; Nasrabadi, H.T.; Joo, S.W.; Hanifehpour, Y.; Nejati-Koshki, K.; Pashaei-Asl, R. Dendrimers: Synthesis, applications, and properties. Nanoscale Res. Lett. 2014, 9, 247.
  28. Noriega-Luna, B.; Godínez, L.A.; Rodríguez, F.J.; Rodríguez, A.; Zaldívar-Lelo de Larrea, G.; Sosa-Ferreyra, C.F.; Mercado-Curiel, R.F.; Manríquez, J.; Bustos, E. Applications of Dendrimers in Drug Delivery Agents, Diagnosis, Therapy, and Detection. J. Nanomater. 2014, 2014, 507273.
  29. Duncan, R.; Izzo, L. Dendrimer biocompatibility and toxicity. Adv. Drug Deliv. Rev. 2005, 57, 2215–2237.
  30. Choudhary, S.; Gupta, L.; Rani, S.; Dave, K.; Gupta, U. Impact of Dendrimers on Solubility of Hydrophobic Drug Molecules. Front. Pharm. 2017, 8, 261.
  31. Alven, S.; Aderibigbe, B.A. The Therapeutic Efficacy of Dendrimer and Micelle Formulations for Breast Cancer Treatment. Pharmaceutics 2020, 12, 1212.
  32. Trembleau, L.; Simpson, M.; Cheyne, R.W.; Escofet, I.; Appleyard, M.V.C.A.L.; Murray, K.; Sharp, S.; Thompson, A.M.; Smith, T.A.D. Development of 18F-fluorinatable dendrons and their application to cancer cell targeting. New J. Chem. 2011, 35, 2496–2502.
  33. Liu, M.; Fréchet, J.M. Designing dendrimers for drug delivery. Pharm. Sci. Technol. Today 1999, 2, 393–401.
  34. Menjoge, A.R.; Kannan, R.M.; Tomalia, D.A. Dendrimer-based drug and imaging conjugates: Design considerations for nanomedical applications. Drug Discov. Today 2010, 15, 171–185.
  35. Wang, J.; Li, B.; Qiu, L.; Qiao, X.; Yang, H. Dendrimer-based drug delivery systems: History, challenges, and latest developments. J. Biol. Eng. 2022, 16, 18.
  36. Najlah, M.; Freeman, S.; Attwood, D.; D’Emanuele, A. In vitro evaluation of dendrimer prodrugs for oral drug delivery. Int. J. Pharm. 2007, 336, 183–190.
  37. Kolhe, P.; Khandare, J.; Pillai, O.; Kannan, S.; Lieh-Lai, M.; Kannan, R. Hyperbranched polymer-drug conjugates with high drug payload for enhanced cellular delivery. Pharm. Res. 2004, 21, 2185–2195.
  38. Patel, V.; Rajani, C.; Paul, D.; Borisa, P.; Rajpoot, K.; Youngren-Ortiz, S.R.; Tekade, R.K. Chapter 8—Dendrimers as novel drug-delivery system and its applications. In Drug Delivery Systems; Tekade, R.K., Ed.; Academic Press: Cambridge, MA, USA, 2020; pp. 333–392.
  39. Rai, D.B.; Gupta, N.; Pooja, D.; Kulhari, H. Dendrimers for diagnostic applications. In Pharmaceutical Applications of Dendrimers; Chauhan, A., Kulhari, H., Eds.; Elsevier: Amsterdam, The Netherlands, 2020; pp. 291–324.
  40. Zhao, J.; Zhang, B.; Shen, S.; Chen, J.; Zhang, Q.; Jiang, X.; Pang, Z. CREKA peptide-conjugated dendrimer nanoparticles for glioblastoma multiforme delivery. J. Colloid. Interface Sci. 2015, 450, 396–403.
  41. Sharma, A.; Porterfield, J.E.; Smith, E.; Sharma, R.; Kannan, S.; Kannan, R.M. Effect of mannose targeting of hydroxyl PAMAM dendrimers on cellular and organ biodistribution in a neonatal brain injury model. J. Control. Release 2018, 283, 175–189.
  42. Srinageshwar, B.; Peruzzaro, S.; Andrews, M.; Johnson, K.; Hietpas, A.; Clark, B.; McGuire, C.; Petersen, E.; Kippe, J.; Stewart, A.; et al. PAMAM Dendrimers Cross the Blood-Brain Barrier When Administered through the Carotid Artery in C57BL/6J Mice. Int. J. Mol. Sci. 2017, 18, 628.
  43. Srinageshwar, B.; Dils, A.; Sturgis, J.; Wedster, A.; Kathirvelu, B.; Baiyasi, S.; Swanson, D.; Sharma, A.; Dunbar, G.L.; Rossignol, J. Surface-Modified G4 PAMAM Dendrimers Cross the Blood–Brain Barrier Following Multiple Tail-Vein Injections in C57BL/6J Mice. ACS Chem. Neurosci. 2019, 10, 4145–4150.
  44. Yiyun, C.; Tongwen, X. Dendrimers as potential drug carriers. Part I. Solubilization of non-steroidal anti-inflammatory drugs in the presence of polyamidoamine dendrimers. Eur. J. Med. Chem. 2005, 40, 1188–1192.
  45. Hawker, C.J.; Wooley, K.L.; Fréchet, J.M.J. Unimolecular micelles and globular amphiphiles: Dendritic macromolecules as novel recyclable solubilization agents. J. Chem. Soc. Perkin Trans. 1993, 1, 1287–1297.
  46. Vaidya, A.; Jain, S.; Pathak, K.; Pathak, D. Dendrimers: Nanosized Multifunctional Platform for Drug Delivery. Drug Deliv. Lett. 2018, 8, 3–19.
  47. Singh, J.; Jain, K.; Mehra, N.K.; Jain, N.K. Dendrimers in anticancer drug delivery: Mechanism of interaction of drug and dendrimers. Artif. Cells Nanomed. Biotechnol. 2016, 44, 1626–1634.
  48. Jain, K.; Kesharwani, P.; Gupta, U.; Jain, N.K. Dendrimer toxicity: Let’s meet the challenge. Int. J. Pharm. 2010, 394, 122–142.
  49. Pinto, S.N.; Mil-Homens, D.; Pires, R.F.; Alves, M.M.; Serafim, G.; Martinho, N.; Melo, M.; Fialho, A.M.; Bonifácio, V.D.B. Core–shell polycationic polyurea pharmadendrimers: New-generation of sustainable broad-spectrum antibiotics and antifungals. Biomater. Sci. 2022, 10, 5197–5207.
  50. Pryor, J.B.; Harper, B.J.; Harper, S.L. Comparative toxicological assessment of PAMAM and thiophosphoryl dendrimers using embryonic zebrafish. Int. J. Nanomed. 2014, 9, 1947–1956.
  51. Singh, V.; Sahebkar, A.; Kesharwani, P. Poly (propylene imine) dendrimer as an emerging polymeric nanocarrier for anticancer drug and gene delivery. Eur. Polym. J. 2021, 158, 110683.
  52. Zhang, J.; Liu, D.; Zhang, M.; Sun, Y.; Zhang, X.; Guan, G.; Zhao, X.; Qiao, M.; Chen, D.; Hu, H. The cellular uptake mechanism, intracellular transportation, and exocytosis of polyamidoamine dendrimers in multidrug-resistant breast cancer cells. Int. J. Nanomed. 2016, 11, 3677–3690.
  53. Shinde Patil, V.R.; Campbell, C.J.; Yun, Y.H.; Slack, S.M.; Goetz, D.J. Particle diameter influences adhesion under flow. Biophys. J. 2001, 80, 1733–1743.
  54. Bamrungsap, S.; Zhao, Z.; Chen, T.; Wang, L.; Li, C.; Fu, T.; Tan, W. Nanotechnology in therapeutics: A focus on nanoparticles as a drug delivery system. Nanomedicine 2012, 7, 1253–1271.
  55. Kitchens, K.M.; Foraker, A.B.; Kolhatkar, R.B.; Swaan, P.W.; Ghandehari, H. Endocytosis and interaction of poly (amidoamine) dendrimers with Caco-2 cells. Pharm. Res. 2007, 24, 2138–2145.
  56. Kitchens, K.M.; Kolhatkar, R.B.; Swaan, P.W.; Ghandehari, H. Endocytosis inhibitors prevent poly(amidoamine) dendrimer internalization and permeability across Caco-2 cells. Mol. Pharm. 2008, 5, 364–369.
  57. Albertazzi, L.; Serresi, M.; Albanese, A.; Beltram, F. Dendrimer internalization and intracellular trafficking in living cells. Mol. Pharm. 2010, 7, 680–688.
  58. Hong, S.; Bielinska, A.U.; Mecke, A.; Keszler, B.; Beals, J.L.; Shi, X.; Balogh, L.; Orr, B.G.; Baker, J.R., Jr.; Banaszak Holl, M.M. Interaction of Poly(amidoamine) Dendrimers with Supported Lipid Bilayers and Cells: Hole Formation and the Relation to Transport. Bioconjugate Chem. 2004, 15, 774–782.
  59. Jahanafrooz, Z.; Mokhtarzadeh, A. Pore-forming Peptides: A New Treatment Option for Cancer. Curr. Med. Chem. 2022, 29, 4078–4096.
  60. Chernyshova, D.N.; Tyulin, A.A.; Ostroumova, O.S.; Efimova, S.S. Discovery of the Potentiator of the Pore-Forming Ability of Lantibiotic Nisin: Perspectives for Anticancer Therapy. Membranes 2022, 12, 1166.
  61. Tajarobi, F.; El-Sayed, M.; Rege, B.D.; Polli, J.E.; Ghandehari, H. Transport of poly amidoamine dendrimers across Madin-Darby canine kidney cells. Int. J. Pharm. 2001, 215, 263–267.
  62. Szwed, A.; Miłowska, K.; Michlewska, S.; Moreno, S.; Shcharbin, D.; Gomez-Ramirez, R.; de la Mata, F.J.; Majoral, J.P.; Bryszewska, M.; Gabryelak, T. Generation Dependent Effects and Entrance to Mitochondria of Hybrid Dendrimers on Normal and Cancer Neuronal Cells In Vitro. Biomolecules 2020, 10, 427.
  63. Albertazzi, L.; Storti, B.; Marchetti, L.; Beltram, F. Delivery and subcellular targeting of dendrimer-based fluorescent pH sensors in living cells. J. Am. Chem. Soc. 2010, 132, 18158–18167.
  64. Mukherjee, S.P.; Lyng, F.M.; Garcia, A.; Davoren, M.; Byrne, H.J. Mechanistic studies of in vitro cytotoxicity of poly(amidoamine) dendrimers in mammalian cells. Toxicol. Appl. Pharm. 2010, 248, 259–268.
  65. Czarnomysy, R.; Muszyńska, A.; Rok, J.; Rzepka, Z.; Bielawski, K. Mechanism of Anticancer Action of Novel Imidazole Platinum(II) Complex Conjugated with G2 PAMAM-OH Dendrimer in Breast Cancer Cells. Int. J. Mol. Sci. 2021, 22, 5581.
  66. Zhang, X.; Zhang, Z.; Xu, X.; Li, Y.; Li, Y.; Jian, Y.; Gu, Z. Bioinspired therapeutic dendrimers as efficient peptide drugs based on supramolecular interactions for tumor inhibition. Angew. Chem. Int. Ed. Engl. 2015, 54, 4289–4294.
  67. Antunes, P.; Cruz, A.; Barbosa, J.; Bonifácio, V.D.B.; Pinto, S.N. Lipid Droplets in Cancer: From Composition and Role to Imaging and Therapeutics. Molecules 2022, 27, 991.
  68. Sharma, A.; Khatchadourian, A.; Khanna, K.; Sharma, R.; Kakkar, A.; Maysinger, D. Multivalent niacin nanoconjugates for delivery to cytoplasmic lipid droplets. Biomaterials 2011, 32, 1419–1429.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Video Production Service
Feedback